Research Topics
| T LebretSummaryAffiliation: Hopital Foch Country: France Publications
| Collaborators
|
Detail Information
Publications
[Study of survival after cystectomy for bladder cancer. Report of 504 cases]T Lebret
Service d Urologie, Hopital Foch, Suresnes, France
Prog Urol 10:553-60. 2000....
[Treatment of bladder tumors]Thierry Lebret
Service d urologie Hôpital Foch 92151 Suresnes
Rev Prat 52:36-42. 2002..To prevent recurrence, both (superficial or infiltrating) tumour require very strict follow-up for many years...
Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunctionThierry Lebret
Urology Department, Hopital Foch, Suresnes 92151, France
Eur Urol 41:608-13; discussion 613. 2002....
After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer?Thierry Lebret
Department of Urology, Hopital Foch, 40 rue Worth, 92151 Suresnes, France
Eur Urol 42:344-9; discussion 349. 2002..The aim of this study was to evaluate the outcome of patients who underwent neobladder replacement despite bladder cancer metastasis to the regional lymph nodes...
[Are therapeutics decisions homogeneous in multidisciplinary onco-urology staff meeting? Comparison of therapeutic options taken in four departments from Paris]F Audenet
Service d Urologie, Universite Paris Descartes, Hopital Europeen Georges Pompidou, AP HP, 20, rue Leblanc, 75015 Paris, France
Prog Urol 22:433-7. 2012..The aim of this study was to compare the therapeutic decision taken in four RCP in Paris Île-de-France academic centres for three identical cases...
Electrovaporization of the prostate with the Gyrus deviceH Botto
Department of Urology H pital Foch, Suresnes, France
J Endourol 15:313-6. 2001..e., 1-year follow-up) should be evaluated. This pilot series permits a comparative study with TURP to assess the benefits for patients and the health care system...
[Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer]M O Timsit
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S365-75. 2008..Early introduction of docetaxel raises the issue of when to start chemotherapy as it may be relevant to initiate this treatment before the onset of hormone independence. GETUG 15 trial will try to answer this question...
[The impact of partial nephrectomy on morbidity and on long-term oncological outcomes]Y Rouach
Service d Urologie, Hopital Necker, Universite Rene Descartes, 69, rue Saint Martin, 75004 Paris, France
Prog Urol 19:481-6. 2009..To evaluate the impact of imperative indication on the rate of complications and long term carcinological results after partial nephrectomy (PN)...
[Is the cytoreductive nephrectomy still necessary in case of metastases?]T Lebret
Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
Prog Urol 20:S33-7. 2010..Until results of prospective studies, the cytoreductive nephrectomy should be still considered as component of the treatment of metastatic renal cell carcinoma...
[Medical treatment of metastatic germ cell cancers]M O Timsit
Service d Urologie, Université Paris Descartes Hôpital Necker, France
Prog Urol 18:S376-81. 2008..Precise predictive factors of recurrence are needed to better define indications of first and other lines of treatment in specific situations such as non-resected residual seminoma...
[Angiogenesis: the renal cancer model]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S309-14. 2008..VEGF binds to his receptors present on endothelial cells to promote tumoral angiogenesis. Targeted therapy inhibit tumoral blood vessels growth and involves probably others complex mechanisms...
[Rare locations of metastases from germ cell cancers]Y Neuzillet
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S388-91. 2008..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary prostate carcinoma lesions...
[Rare locations of metastases from penile cancer]Y Neuzillet
Service d Urologie, Hopital Foch, Faculté de médecine Paris Ouest UVSQ, France
Prog Urol 18:S396-8. 2008..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary urothelial carcinoma lesions...
[Rare locations of metastases from renal carcinoma]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S320-6. 2008..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary renal carcinoma lesions...
[Oncogeriatric evaluation for elderly patients suffering from metastatic urologic malignancies]Y Neuzillet
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S415-25. 2008..The scales of assessment of competitive morbidity and measurement of the level of activity now available provide useful prognostic information to help the urologist to make the best decision concerning the therapeutic approach...
[Functional evaluation of the orthotopic Z-shaped ileal detubulated neobladder with a minimal 5-year follow-up]M Demesmaeker
Service d Urologie, Hopital Foch, Suresnes, France
Prog Urol 20:49-55. 2010..Study and evaluate the orthotopic Z-shaped neobladder in the long term and life quality of patients bearing this type of replacement...
[Metastatic diffusion, angiogenesis and metastasogenesis]A Mejean
Service d Urologie, Hopital Necker, Universite Paris Descartes, 149 rue de Sevres, Paris, France
Prog Urol 20:S5-10. 2010..At the opposite, the concept of a metastatic gene expression pattern which is (or is not) expressed in the primary tumor is in opposition with the classical clonal selection hypothesis...
[Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer]T Lebret
Service d Urologie, Hopital Foch, Faculté de Médecine de Paris Ile de France Ouest, UVSQ, 40, rue Worth, 92150 Suresnes, France
Prog Urol 21:301-7. 2011....
[Management of the side effects of androgenic deprivation]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S338-42. 2008..They can and must be prevented by advice on physical activity and nutrition...
A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunctionY Neuzillet
Department of Urology, Hopital Foch, Suresnes, France
Andrology 1:223-8. 2013....
[Management of toxicities due to anti-angiogenic treatment of metastatic renal carcinoma]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S315-9. 2008..The consequences on the physiological microvasculature could be at the origin of the adverse effects. It seems important for the clinician to know the physiopathology and the management of these toxicities...
[Role of hormonotherapy in the treatment of metastatic prostate cancer]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S332-7. 2008....
[Rare locations of metastases from prostate cancer]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ Hôpital Necker, France
Prog Urol 18:S357-64. 2008..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary prostate carcinoma lesions...
[Supportive care for urological metastatic patients]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S410-4. 2008..It also includes financial allowances. In France, supportive care centers are being set up in most hospital to facilitate the coordination of all the multidisciplinary teams...
[How to manage bone metastasis in prostate cancer. A case report]T Lebret
Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
Prog Urol 20:S72-6. 2010..Metastasis surgery has functional results and should be performed before major neurologic symptoms occur. Metabolic radiotherapy is an option for multifocal bone metastases...
[Healing and targeted therapies: Management in perioperative period?]G Pignot
Service d Urologie, Hopital Cochin, Universite Rene Descartes, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
Prog Urol 21:166-72. 2011....
[Metastastic urothelial carcinoma: is there a role for surgery?]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S285-8. 2008..Metastasis resection can also be proposed in association with chemotherapy in case of complete response. In case of non responsive metastasis, metastasectomy can also de discussed in order to improve quality of life...
[PET-FDG in metastases from urological malignancies]P Labarthe
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S208-12. 2008..Nevertheless, interpretation is often made difficult by tracer urinary excretion. New radio tracers are being tested and will probably lead to new indications. Research on androgen receptors and molecular imaging is ongoing...
Evaluation of tension-free vaginal tape procedure. Its safety and efficacy in the treatment of female stress urinary incontinence during the learning phaseT Lebret
Department of Urology, Hospital Foch, Suresnes, France
Eur Urol 40:543-7. 2001..Nevertheless, our results confirm that TVT appears to be an efficient procedure: 97% of patients were cured or improved when UCP >25 cm H2O, 85% when UCP <25 cm H2O and 87% when a PR was associated...
[Targeted therapies]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S228-33. 2008..An important number of drugs is still approved. However the metastatic disease is not yet curable. A better understanding will lead to develop others new targeted molecules or more efficient combination therapy...
[Metastases from squamous cell carcinoma of the penis]F Iborra
CHU de Montpellier, Hopital Lapeyronie, Service d Urologie, France
Prog Urol 18:S392-5. 2008..Metastasis diagnosis is carried out with TDM and MRI but markers can sometimes be helpful (ie SSCAg). There is no referent chemotherapy, a trial has been started (CAVER)...
[Bone prevention in prostate cancer]T Bessede
Service d Urologie, Hopital Bicetre, 78, rue du General Leclerc, 94275 Le Kremlin Bicetre cedex, France
Prog Urol 21:S58-62. 2011..These agents may have a preventive effect on metastasis occurrence, but it has to be confirmed. An intra-venous biphosphonate or a sub-cutaneous RANK-inhibitor administration prevent from bone metastasis-related events...
[Metastases from urethelial carcinoma: role of chemotherapy]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S261-76. 2008..After failure of first line therapy no consensual drugs exist in the second line, ongoing trials and new agents should increase options in the future...
[Bladder tumour treatment: the real BCG definitive contra-indications]Y Neuzillet
Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
Prog Urol 20:S41-5. 2010..These specific circumstances require more studies and data if they are no longer to be considered as a contra-indication...
[The journey of a molecule, from trials to approval: the specific area of oncology]T Lebret
Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
Prog Urol 20:S1-4. 2010..Here we discuss the motivations of the pharmaceutical industry in oncology so that the medico-surgical specialist of the cancers of the genito-urinary tract can best understand the situation...
[How to read and assess oncological scientific research articles in English?]Y Neuzillet
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S430-4. 2008..Results and statistical analysis should be evaluated by the reviewer, keeping in mind that the weight of evidence is not correlated to the "p" value...
[Treatment of infiltrating nonmetastatic bladder cancers in elderly patients]H Quintens
Service d Urologie, Institut A Tzanck, Avenue du Docteur Dodat, 06700 Nice, France
Prog Urol 19:S135-41. 2009..Thus, with multidisciplinary consensus and adapted management, elderly patients with significant comorbidities should not be automatically excluded from access to effective treatment of these cancers...
[Physiopathology, diagnosis and management of bone metastases from prostate cancer]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S349-56. 2008..Endothelin inhibitors belong to a new exciting concept to treat these bone metastases, data are needed in order to use them routinely...
[Management of metastatic androgeno-independent prostate cancer]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S343-8. 2008..It is also possible to use estrogen or, in a few cases, to propose chemotherapy...
[Bladder replacement and cancer of the bladder]T Lebret
Service d Urologie, Hopital Foch, Suresnes, France
Prog Urol 19:872-80. 2009..The correct functioning of the neo-bladder should be verified regularly in order to ensure that the bladder is emptied properly. Continence returns through auto-exercise...
[Metastases from urothelial carcinoma : future and prospects]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S277-84. 2008..Furthermore, the development of the concept of individualized treatment through identification of molecular prognostic factors and the application of targeted therapy have gained huge interest...
[Role and technical aspects of surgery for spinal metastases from urological malignancies]S Gaillard
Service de Neurochirurgie, Hopital Foch, Suresnes, France
Prog Urol 18:S239-45. 2008..The choices of therapeutic approach are quite large ranging from percutaneous cimentoplasty to vertebral replacement. It is essential that the initial treatment of metastasis be discussed before neurologic signs appear...
[Rare locations of metastases from urothelial carcinoma]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S289-97. 2008..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary urothelial carcinoma lesions...
[Prise en charge of metastatic renal carcinoma]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S298-308. 2008..Because of a poor prognosis trials testing combination of therapies are required to benefit patients. At least nephrectomy is necessary looking forward prospective studies to estimate its real impact...
[Targets, pathways and molecules]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S173-7. 2008..Thus it is possible to define targets which can be receptors, molecules or proteins and consequently develop active drugs for targeted therapy...
[The metastatic cascade: angiogenesis and new concepts]A Mejean
Service d Urologie, Universite Paris Descartes, France
Prog Urol 18:S156-66. 2008..The capacity to colonize one organ and not another could be explained by the "seed and soil" theory which postulates that tumor cells (the seed) will only grow in an...
[The natural history of metastatic prostate cancer]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
Prog Urol 18:S327-31. 2008..At each step of the metastatic cascade, it is possible to imagine a specific targeted therapy for this disease which is today non curable...
[The physiopathology of metastases: from primary to secondary]T Lebret
Service d Urologie, Hopital Foch, Faculté de médecine Paris Ouest UVSQ
Prog Urol 18:S147-55. 2008..At each step, there are defence and regulation mechanisms which, when they fail, lead to metastatic dissemination...
Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissueV Hupertan
Department of Urology, Hopital Bichat, Paris, France
Int J Androl 35:860-6. 2012..The present data indicate that a 'NO donor' combined with an 'adenosine donor' could be an effective therapeutic approach...
[Indications of ablative therapies in the treatment of kidney cancer in the elderly]L Froger
Service d Urologie, CHU Saint Louis, Paris, France
Prog Urol 22:1004-9. 2012..Approximately, 30% of kidney cancers are diagnosed in patients over 75 years, mostly by fortuitously. This review had identified the indications of ablative treatment among others options for kidney cancer in these elderly patients...
[Patient information and professional responsibility: reversal of jurisprudence of the Court of cassation]M Rouanne
Service d Urologie, Faculte de Medecine Paris Ile de France Ouest, Hopital Foch, UVSQ, 40, rue Worth, 92150 Suresnes, France
Prog Urol 22:67-9. 2012..In accordance with this decision, a new jurisprudence in medical responsibility is born...
[Urolithiasis, CT and lithotripsy guidelines]A Scherrer
Service de Radiologie, Hopital Foch, Suresnes, France
J Radiol 81:1039-51. 2000..practitioner, the radiologist and the urologist should answer three questions that will be reviewed in this paper: Is the acute flank pain caused by urolithiasis? Will calculus be spontaneously discharged? Is lithotripsy indicated?..
[Metastases from urologic malignancies: history, definitions and strategies]T Lebret
Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ
Prog Urol 18:S143-6. 2008..Today, even if all is not totally understood, physicians know that metastasis is a decisive event in the carcinoma story...
TSC2/PKD1 contiguous gene syndrome in an adultT Culty
Department of Urology, CHU Pitie Salpetriere, Paris, France
Minerva Urol Nefrol 58:351-4. 2006..The clinical and pathological presentation is consistent with the diagnosis of TSC2/PKD1 contiguous gene syndrome, caused by the simultaneous loss of TSC2 and PKD1, the two major genes for tuberous sclerosis complex and ADPKD...
[Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?]Thierry Lebret
Service d Urologie, Hopital Foch, 40 rue Worth, Suresnes, France
Prog Urol 18:S111-4. 2008..In both cases (early, before BCG treatment, or after BCG treatment failure), this excision therapy should be practiced rapidly because the risk of progression is high and cystectomy tolerates no delay when indicated...
Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?Laurent Guy
Department of Urology, CHU Clermont Ferrand, France
Eur Urol 50:516-20; discussion 520. 2006..Vesical biopsies often are performed to assess the efficacy of treatment. The aim of our study was to evaluate the usefulness of these biopsies...
HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumoursThierry Lebret
Department of Urology and Pathology, Hopital Foch, Suresnes, France
Eur Urol 51:161-6; discussion 166-7. 2007..This study attempted to evaluate if heat shock proteins (HSPs) could be useful predictive markers in BCG responses...
[Urothelial tumors]Jacques Irani
Prog Urol 14:957, 959-96. 2004
[Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]Jacques Irani
Comite Tumeurs Urothéliales du CCAFU
Prog Urol 15:581-6. 2005....
Treatment of postprostatectomy stress urinary incontinence using a minimally invasive adjustable continence balloon device, ProACT: results of a preliminary, multicenter, pilot studyThierry Lebret
Department of Urology, Hopital Foch, Suresnes, France
Urology 71:256-60. 2008..To evaluate the safety and efficacy of a new minimally invasive device, Adjustable Continence Therapy (ProACT) for patients with postprostatectomy stress urinary incontinence (SUI)...
[Urothelial tumors]Jacques Irani
Prog Urol 17:1065-98. 2007
[Upper urinary tract tumor: conservative treatment of localized forms]Jacques Irani
Service d'Urologie, , 86000 Poitiers
Prog Urol 13:555-9. 2003
[Infiltrating bladder tumours]Thierry Lebret
Service d Urologie, Hopital Foch, 92150 Suresnes
Rev Prat 57:630-40. 2007..In case of recurrence, therapeutic options should be debated in multidisciplinary team meetings; chemotherapy with cisplatin or/and gemcitabine remains the main therapeutic weapon...
Peyronie's diseaseJohn Pryor
Institute of Urology, London University, London, UK
J Sex Med 1:110-5. 2004..Peyronie's disease is a sexual medicine condition that may adversely affect male sexual function...
[Superficial grade G2 tumors of the bladder: recurrence, progression, prognosis]Philippe Sebe
Service d'Urologie, , 40, rue Worth, BP 36, 92150 Suresnes
Prog Urol 13:608-12. 2003..These tumours have a high recurrence risk with a cystectomy rate of 16%. These tumours require surveillance identical to that of high-grade tumours, at least half-yearly for the first 3 years then annually thereafter...
Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patientsHenry Botto
Department of Urology, Hopital Foch, Suresnes, France
BJU Int 94:1021-5. 2004....
